



A.



Supplemental Figure 2 . Differences in co-mutations and immune markers between patients with KRAS mutated (KRAS MT) NSCLC with or without an ATM mutation (ATM MT; A) and between patients with KRAS mutated (KRAS MT) NSCLC with or without a U2AF1 co-mutation (U2AF1 MT; B). (A) Frequency of the 10 most common co-occurring mutations as well as TMB high in patients with tumors harboring KRAS mutations with or without an ATM mutation. (B) Frequency of the 10 most common co-occurring mutation in patients with tumors harboring both KRAS mutations with or without U2AF1 mutations.

B.



**q<0.05
* p<0.05